• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News > DNDi 2021 Projects of the Year recognize partners and colleagues for their work in developing new treatments for visceral leishmaniasis and sleeping sickness > Page 9

DNDi 2021 Projects of the Year recognize partners and colleagues for their work in developing new treatments for visceral leishmaniasis and sleeping sickness

6 Oct 2021
  • English
    • English
    • Français
    • 日本語

The Drugs for Neglected Diseases initiative (DNDi) is very pleased to announce two 2021 Projects of the Year, which recognize DNDi R&D teams and key partners for outstanding progress in the areas of drug discovery and clinical research. Nominated by the DNDi Scientific Advisory Committee and selected by the DNDi Executive Board, the 2021 awards recognize two projects from among the more than 50 active projects in DNDi’s R&D portfolio.

S07 series lead optimization for visceral leishmaniasis – 2021 Project of the Year in drug discovery

Existing treatments for visceral leishmaniasis can be painful, toxic, lengthy, costly, and poorly adapted for use in the most affected communities. To provide people of all ages with safer, simpler, and more effective treatment options, DNDi and partners are discovering entirely new compounds that can be developed into all-oral drugs.

The S07 series is the first project to emerge into lead optimization from the NTD Drug Discovery Booster, a global consortium of pharmaceutical companies that have opened their libraries of millions of unique molecules so that researchers can screen them in silico and in vitro to identify new potential treatments for neglected tropical diseases. With support from the Japanese Global Health Innovative Technology (GHIT) Fund, among other donors, more than 18,000 compounds have been screened for antiparasitic activity to date through this international initiative.

Following Discovery Booster efforts conducted in partnership with Takeda Pharmaceutical Company Limited to identify and advance novel compounds against visceral leishmaniasis, the DNDi-Takeda collaboration is now progressing medicinal chemistry optimization for S07 series lead compounds to further enhance their safety and efficacy profiles. With support from the GHIT Fund, the partnership aims to advance an optimized lead to deliver a pre-clinical candidate compound by 2023.

‘The S07 series is a prime example of the advances our discovery partnerships are making to find the missing tools we need to meet patient’s needs and reach global targets for neglected tropical diseases,’ said Dr Laurent Fraisse, Research and Development Director at DNDi. ‘We congratulate Takeda and the DNDi Drug Discovery team for their progress, which demonstrates that innovative collaborations like the NTD Drug Discovery Booster can play a powerful role in accelerating scientific discovery and future medical innovation.’

Acoziborole for sleeping sickness – 2021 Project of the Year in clinical research

DNDi’s goal is to revolutionize the treatment of sleeping sickness – or human African trypanosomiasis (HAT) – by replacing toxic, cumbersome medicines with simple, all-oral cures that can help eliminate the disease altogether. In 2018, DNDi and partners completed the development of the first all-oral treatment for sleeping sickness, fexinidazole.

Together with Sanofi, our industrial partner for fexinidazole, we are now working to complete the development of acoziborole, a single-dose oral treatment for sleeping sickness that can be administered at the point of diagnosis.

‘Acoziborole can provide a dramatic boost for sleeping sickness ‘test-and-treat’ programmes – particularly in remote communities and settings affected by conflict and instability – and help anchor efforts to sustain elimination of the disease,’ said Dr Fraisse. ‘These advances in clinical development would not be possible without the steady commitment of Sanofi, the Institut National de Recherche Biomédicale (INRB) of the Democratic Republic of Congo (DRC), the National HAT Control Programmes of the DRC and Guinea, and the DNDi sleeping sickness team.’

In 2012, acoziborole became the first new chemical entity to enter clinical development from DNDi’s own lead optimization programme. Last year, our teams completed 18-month post treatment follow-up for all patients in DNDi’s pivotal Phase II/III clinical trial for the drug in the Democratic Republic of Congo (DRC) and Guinea. Following its approval, Sanofi will be responsible for the manufacturing, supply, registration, and distribution of acoziborole. The treatment will be provided to patients free of charge through affected countries’ public health systems thanks to a 20-year collaboration between Sanofi and the World Health Organization.

Read more about visceral leishmaniasis

Read more about sleeping sickness

Clinical trials Drug discovery Sleeping sickness Visceral leishmaniasis

Read, watch, share

Loading...
The Star logo
Viewpoints
10 Jul 2024

What Kenya can do to achieve its elimination targets for neglected diseases

The Star
Doctor holding treatment box
Press releases
1 Jul 2024

WHO recommends first all-oral treatment for acute sleeping sickness found in Eastern and Southern Africa

Two people working in a lab
Press releases
24 Jun 2024

Paediatric malaria treatment developed in Brazil by not-for-profit organizations distributed to Indigenous children in the Amazon region

Two healthcare workers
Press releases
12 Jun 2024

New framework for visceral leishmaniasis elimination launched for Eastern Africa

LEAP Platform video thumbnail
Videos
30 May 2024

Celebrating 20 Years of LEAP: Innovation and Impact

Statements
28 May 2024

DNDi interventions at the 77th World Health Assembly

Dr Loyce Faith Nangiro visting a patient on the ward
Stories
23 May 2024

Defying the odds: One doctor’s remarkable journey to helping patients with kala-azar

Statements
21 May 2024

DNDi’s briefing note for 77th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License